A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL

International Journal of Hematology

Volumn 89, Issue 5, 2009, Pages 679-688

  Tojo, Arinobu ^a   Usuki, Kensuke ^b   Urabe, Akio ^b   Maeda, Yasuhiro ^c   Kobayashi, Yukio ^d   Jinnai, Itsuro ^e   Ohyashiki, Kazuma ^f   Nishimura, Miki ^g   Kawaguchi, Tatsuya ^h   Tanaka, Hideo ⁱ   Miyamura, Koichi ^j   Miyazaki, Yasushi ^k   Hughes, Timothy ^l   Branford, Susan ^l   Okamoto, Shinichiro ^m   Ishikawa, Jun ⁿ   Okada, Masaya ^o   Usui, Noriko ^p   Tanii, Hiromi ^q   Amagasaki, Taro ^q   Natori, Hiroko ^q   Naoe, Tomoki ^r   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b Kanto Teishin Hospital   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^g CHIBA UNIVERSITY HOSPITAL   (Japan)

^h KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

ⁱ HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^j JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^k NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^l HANSON INSTITUTE   (Australia)

^m KEIO UNIVERSITY HOSPITAL   (Japan)

ⁿ OSAKA UNIVERSITY HOSPITAL   (Japan)

^o HYOGO COLLEGE OF MEDICINE HOSPITAL   (Japan)

^p JIKEI UNIVERSITY HOSPITAL   (Japan)

^q Japan Pharmaceutical Association   (Japan)

^r NAGOYA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

BCR ABL; CML; Imatinib resistant; Nilotinib; Ph+ ALL

Indexed keywords

BCR ABL PROTEIN; IMATINIB; NILOTINIB;

ABNORMAL LABORATORY RESULT; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CYTOGENETICS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEADACHE; HUMAN; JAPANESE; LIVER DYSFUNCTION; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUTROPENIA; PANCREATITIS; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRURITUS; QT PROLONGATION; SIDE EFFECT; STOMACH DISCOMFORT; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 67749145142     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0327-0     Document Type: Article

References (16)

1. S Faderl M Talpaz Z Estrov 1999 The biology of chronic myeloid leukemia N Engl J Med 341 164 172 10.1056/NEJM199907153410306 (Pubitemid 29325745)
2. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340 10.1056/NEJM199904293401706 (Pubitemid 29196596)
3. JE Sokal M Baccarani D Russo 1998 Staging and prognosis in chronic myelogenous leukemia Semin Hematol 25 49 61
4. RT Maziarz 2005 Ph+ ALL: another success for imatinib Blood 105 9 3388 3389 10.1182/blood-2005-02-0708
5. SG O'Brien F Guilhot RA Larson 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 (Pubitemid 36302244)
6. B Druker F Guilhot SG O'Brien 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 10.1056/NEJMoa062867 (Pubitemid 44903745)
7. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. Advance online publication 12 Mar 2009. doi: 10.1038/leu.2009.38.
8. PW Manley J Brüggen D Fabbro 2007 Extended kinase profiling of the Bcr-Abl inhibitor nilotinib Proc Am Assoc Cancer Res 48 772 Abstract 3249
9. E Weisberg P Manley J Mestan 2006 AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 1765 1769 10.1038/sj.bjc.6603170 (Pubitemid 43882564)
10. HM Kantarjian F Giles N Gattermann 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 10 3540 3546 10.1182/blood-2007-03-080689 (Pubitemid 350159618)
11. HM Kantarjian A Hochhaus J Cortes 2007 Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance Blood 110 226a (Abstract 735)
12. P le Coutre FJ Giles J Apperley 2008 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib resistance or intolerance accelerated-phase chronic myelogenous leukemia Blood 111 4 1834 1839 10.1182/blood-2007-04-083196
13. FJ Giles RA Larson HM Kantarjian 2007 Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib Blood 110 310a (Abstract 1025)
14. Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood. 2007;110:(Abstract 2815).
15. Tojo A, Miyazaki Y, Usui N, et al. Phase I study of nilotinib in patients from Japan with imatinib-resistant Ph+ chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL). J Clin Oncol. 2007;25:(Abstract 17511).
16. HM Kantarjian F Giles L Wunderle 2006 Nilotinib imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 2542 2551 10.1056/NEJMoa055104 (Pubitemid 43882350)